NCT00562770View on ClinicalTrials.gov

Oral Valganciclovir Versus Valacyclovir

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

July 31, 2006

Conditions
Chronic Lymphocytic LeukemiaLeukemia
Interventions
DRUG

Valganciclovir

900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.

DRUG

Valacyclovir

500 mg po QD during therapy and for 2 months post alemtuzumab initiation.

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00562770 - Oral Valganciclovir Versus Valacyclovir | Biotech Hunter | Biotech Hunter